Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2023American Journal of HematologyOpen Access

Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWan‐Hsuan LeeCLChien‐Chin LinCTCheng‐Hong Tsai

Discussion

Loading...

Member takes

Overview

Cohort study reveals distinct mutational profiles and outcomes in patients reclassified under 2022 ICC myelodysplastic criteria, highlighting improved clinical risk stratification.

Key Points

  • Evaluate the clinical, genetic, and prognostic relevance of the 2022 International Consensus Classification (ICC) system in patients originally diagnosed with myelodysplastic syndrome under the 2016 WHO criteria.
  • Analyzed clinico-genetic and survival data from 716 patients with primary myelodysplastic syndrome (MDS) previously classified according to 2016 WHO guidelines.
  • Reclassified patients according to 2022 ICC criteria by assessing blast percentages and key gene mutations, including SF3B1 and TP53.
  • After excluding 15 patients reclassified to AML, 75.3% remained in the MDS group and 24.7% were reclassified to the MDS/AML category under the ICC.
  • Patients reclassified as MDS/AML showed distinct mutational patterns and significantly worse clinical outcomes compared to those who remained in the MDS group.
  • Within MDS, MDS-SF3B1 had higher frequencies of DNMT3A and TET2 mutations, whereas mutated TP53 conferred dismal outcomes irrespective of blast percentage.

Cite This Study

Lee et al. (2023) studied this question.

synapsesocial.com/papers/6a8aeb708c20842028337df3https://doi.org/10.1002/ajh.26799
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms2024 · 29 citations
  2. 2Comparative Analysis of ICC and WHO Classifications Reveals Molecular and Clinical Convergence Between AML-MR and MDS/AML.2026 · 2 citations
  3. 3Validation of ICC hierarchical classification in secondary AML2026 · 3 citations
  4. 4Validation of clinicopathologic features of a genetic myelodysplastic syndrome classification in an independent cohort2025
  5. 5Distinctive Molecular Risk Factors Between <scp>MDS</scp> and <scp>MDS</scp> / <scp>AML</scp> Defined by <scp>ICC</scp>2026 · 1 citations